Administration of melatonin after onset of ischemia reduces the volume of cerebral infarction in a rat middle cerebral artery occlusion stroke model

Stroke

Volumn 34, Issue 3, 2003, Pages 770-775

  Pei, Zhong ^a   Pang, Shiu Fun ^a   Cheung, Raymond Tak Fai ^a,b  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b QUEEN MARY HOSPITAL   (Hong Kong)

Author keywords

Melatonin; Middle cerebral artery occlusion; Neuroprotection; Rats; Stroke, experimental

Indexed keywords

ALTEPLASE; MELATONIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN ISCHEMIA; CELL PROTECTION; CONTROLLED STUDY; DNA DAMAGE; DRUG EFFECT; DRUG EFFICACY; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; MITOCHONDRIAL RESPIRATION; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; REPERFUSION INJURY; RISK BENEFIT ANALYSIS; STROKE;

ANIMALS; BRAIN EDEMA; CEREBRAL INFARCTION; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; INFARCTION, MIDDLE CEREBRAL ARTERY; INJECTIONS, INTRAPERITONEAL; ISCHEMIC ATTACK, TRANSIENT; MALE; MELATONIN; NEUROPROTECTIVE AGENTS; RATS; RATS, SPRAGUE-DAWLEY; REPERFUSION; TIME FACTORS;

EID: 0037335690     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.0000057460.14810.3E     Document Type: Article

References (43)

1. Adams HP Jr, Brott TG, Furlan AJ, Gomez CR, Grotta J, Helgason 1 CM, Kwiatkowski T, Lyden PD, Marler JR, Torner J, Feinberg W, Mayberg M. Thies W. Guidelines for thrombolytic therapy for acute stroke: a supplement to the guidelines for the management of patients with acute ischemic stroke: a statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. Stroke. 1996;27:1711-1718.
2. Alberts MJ. tPA in acute ischemic stroke: United States experience and issues for the future. Neurology. 1998;51(suppl):S53-S55.
3. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581-1587.
4. Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R, Boysen G, Bluhmki E, Hoxter G, Mahagne MH, Hennerici M, for the ECASS Study Group. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: the European Cooperative Acute Stroke Study (ECASS). JAMA. 1995;274:1017-1025.
5. Lipton P. Ischemic cell death in brain neurons. Physiol Rev. 1999;79:1431-1568.
6. Lee JM, Zipfel GJ, Choi DW. The changing landscape of ischaemic brain injury mechanisms. Nature. 1999;399(suppl):A7-A14.
7. White BC, Sullivan JM, DeGracia DJ, O'Neil BJ. Brain ischemia and reperfusion: molecular mechanisms of neuronal injury. J Neurol Sci. 2000;179:1-33.
8. McCulloch J, Dewar D. A radical approach to stroke therapy. Proc Natl Acad Sci U S A. 2001;98:10989-10991.
9. Reiter RJ. Oxidative damage in the central nervous system: protection by melatonin. Prog Neurobiol. 1998;56:359-384.
10. de la Lastra CA, Cabeza J, Motilva V, Martin MJ. Melatonin protects against gastric ischemia-reperfusion injury in rats. J Pineal Res. 1997;23:47-52.
11. Dave RH, Hale SL, Kloner RA. The effect of melatonin on hemodynamics, blood flow, and myocardial infarct size in a rabbit model of ischemia-reperfusion. J Cardiovasc Pharmacol Ther. 1998;3:153-160.
12. Kilic E, Ozdemir YG, Bolay H, Dalkara T. Pinealectomy aggravates and melatonin administration attenuates brain damage in focal ischemia. J Cereb Blood Flow Metab. 1999;19:511-516.
13. Kaneko S, Okumura K, Numaguchi Y, Matsui H, Murase K, Mokuno S, Morishima I, Hira K, Toki Y, Ito T, Hayakawa T. Melatonin scavenges hydroxyl radical and protects isolated rat hearts from ischemic reperfusion injury. Life Sci. 2000;67:101-112.
14. Salie R, Harper I, Cillie C, Genade S, Huisamen B, Moolman J, Lochner A. Melatonin protects against ischaemic-reperfusion myocardial damage. J Mol Cell Cardiol. 2001;33:343-357.
15. Cuzzocrea S, Costantino G, Mazzon E, Micali A, De Sarro A, Caputi AP. Beneficial effects of melatonin in a rat model of splanchnic artery occlusion and reperfusion. J Pineal Res. 2000;28:52-63.
16. Cuzzocrea S, Costantino G, Gitto E, Nazzon E, Fulia F, Serraino I, Cordaro S, Barberi I, De Sarro A, Caputi A. Protective effects of melatonin in ischemic brain injury. J Pineal Res. 2000;29:217-227.
17. Pei Z, Ho HT, Cheung RT. Pre-treatment with melatonin reduces volume of cerebral infarction in a permanent middle cerebral artery occlusion stroke model in the rat. Neurosci Lett. 2002;318:141-144.
18. Pei Z, Pang SF, Cheung RT. Pretreatment with melatonin reduces volume of cerebral infarction in a rat middle cerebral artery occlusion stroke model. J Pineal Res. 2002;32:168-172.
19. Longa EZ, Weinstein PR, Carlson S, Cummins R. Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke. 1989;20:84-91.
20. Cheung RT, Hachinski VC, Cechetto DF. Cardiovascular response to stress after middle cerebral artery occlusion in rats. Brain Res. 1997;747:181-188.
21. Iadecola C, Niwa K, Nogawa S, Zhao X, Nagayama M, Araki E, Morham S, Ross ME. Reduced susceptibility to ischemic brain injury and N-methyl-D-aspartate-mediated neurotoxicity in cyclooxygenase-2-deficient mice. Proc Natl Acad Sci U S A. 2001;98:1294-1299.
22. Cheung RTF, Pei Z, Feng ZH, Zou LY. Cyclooxygenase-1 gene knockout does not alter middle cerebral artery occlusion in a mouse stroke model. Neurosci Lett. 2002;330:57-60.
23. Giusti P, Gusella M, Lipartiti M, Milani D, Zhu W, Vicini S, Manev H. Melatonin protects primary cultures of cerebellar granule neurons from kainate but not from N-methyl-D-aspartate excitotoxicity. Exp Neurol. 1995;131:39-46.
24. Giusti P, Lipartiti M, Franceschini D, Schiavo N, Floreani M, Manev H. Neuroprotection by melatonin from kainate-induced excitotoxicity in rats. FASEB J. 1996;10:891-896.
25. Manev H, Uz T, Kharlamov A, Cagnoli CM, Franceschini D, Giusti P. In vivo protection against kainate-induced apoptosis by the pineal hormone melatonin: effect of exogenous melatonin and circadian rhythm. Restor Neurol Neurosci. 1996;9:251-256.
26. Giusti P, Franceschini D, Petrone M, Manev H, Floreani M. In vitro and in vivo protection against kainate-induced excitotoxicity by melatonin. J Pineal Res. 1996;20:226-231.
27. Manev H, Uz T, Kharlamov A, Joo JY. Increased brain damage after stroke or excitotoxic seizures in melatonin-deficient rats. FASEB J. 1996;10:1546-1551.
28. Joo JY, Uz T, Manev H. Opposite effects of pinealectomy and melatonin administration on brain damage following cerebral focal ischemia in rat. Restor Neurol Neurosci. 1998;13:185-191.
29. Cho S, Joh TH, Baik HH, Dibinis C, Volpe BT. Melatonin administration protects CA1 hippocampal neurons after transient forebrain ischemia in rats. Brain Res. 1997;755:335-338.
30. Guerrero JM, Reiter RJ, Ortiz GG, Pablos MI, Sewerynek E, Chuang JI. Melatonin prevents increases in neural nitric oxide and cyclic GMP production after transient brain ischemia and reperfusion in the Mongolian gerbil (Meriones unguiculatus). J Pineal Res. 1997;23:24-31.
31. Tan DX, Manchester LC, Reiter RJ, Qi WB, Karbownik M, Calvo JR. Significance of melatonin in antioxidative defense system: reactions and products. Biol Signals Recept. 2000;9:137-159.
32. Reiter RJ, Tan DX, Manchester LC, Qi W. Biochemical reactivity of melatonin with reactive oxygen and nitrogen species. Cell Biochem Biophysics. 2001;34:237-256.
33. Morin D, Hauet T, Spedding M, Tillement J. Mitochondria as target for anti-ischemic drugs. Adv Drug Delivery Rev. 2001;49:151-174.
34. Bai J, Cederbaum AI. Mitochondrial catalase and oxidative injury. Biol Signals Recept. 2001;10:189-199.
35. Acuna-Castroviejo D, Martin M. Macias M, Escames G, Leon J, Khaldy H, Reiter RJ. Melatonin, mitochondria, and cellular bioenergetics. J Pineal Res. 2001;30:65-74.
36. Gilad E, Wong HR, Zingarelli B, Virag L, O'Connor M, Salzman AL, Szabo C. Melatonin inhibits expression of the inducible isoform of nitric oxide synthase in murine macrophages: role of inhibition of NFkappaB activation. FASEB J. 1998;12:685-693.
37. Crespo E, Macias M, Pozo D, Escames G, Martin M, Vives F, Guerrero JM, Acuna-Castroviejo D. Melatonin inhibits expression of the inducible NO synthase II in liver and lung and prevents endotoxemia in lipopolysaccharide-induced multiple organ dysfunction syndrome in rats. FASEB J. 1999;13:1537-1546.
38. Cuzzocrea S, Reiter RJ. Pharmacological action of melatonin in shock, inflammation and ischemia/reperfusion injury. Eur J Pharmacol. 2001;426:1-10.
39. Nogawa S, Forster C, Zhang F, Nagayama M, Ross ME, Iadecola C. Interaction between inducible nitric oxide synthase and cyclooxygenase-2 after cerebral ischemia. Proc Natl Acad Sci U S A. 1998;95:10966-10971.
40. del Zoppo G, Ginis I, Hallenbeck JM, Iadecola C, Wang X, Feuerstein GZ. Inflammation and stroke: putative role for cytokines, adhesion molecules and iNOS in brain response to ischemia. Brain Pathol. 2000;10:95-112.
41. Iadecola C, Alexander M. Cerebral ischemia and inflammation. Curr Opin Neurol. 2001;14:89-94.
42. Bubenik GA, Blask DE, Brown GM, Maestroni GJ, Pang SF, Reiter RJ, Viswanathan M, Zisapel N. Prospects of the clinical utilization of melatonin. Biol Signals Recept. 1998;7:195-219.
43. de Lourdes M, Seabra V, Bignotto M, Pinto LR Jr, Tufik S. Randomized, double-blind clinical trial, controlled with placebo, of the toxicology of chronic melatonin treatment. J Pineal Res. 2000;29:193-200.